论文信息 - Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions

Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions

BackgroundNext generation sequencing has a potential to revolutionize the management of cancer patients within the framework of precision oncology. Nevertheless, lack of standardization decelerated entering of the technology into the clinical testing space. Here we dissected a number of common problems of NGS diagnostics in oncology and introduced ways they can be resolved.MethodsDNA was extracted from 26 formalin fixed paraffin embedded (FFPE) specimens and processed with the TrueSeq Amplicon Cancer Panel (Illumina Inc, San Diego, California) targeting 48 cancer-related genes and sequenced in single run. Sequencing data were comparatively analyzed by several bioinformatics pipelines.ResultsLibraries yielded sufficient coverage to detect even low prevalent mutations. We found that the number of FFPE sequence artifacts significantly correlates with pre-normalization concentration of libraries (rank correlation −0.81; p < 1e−10), thus, contributing to sample-specific variant detection cut-offs. Surprisingly, extensive validation of EGFR mutation calls by a combination of aligners and variant callers resulted in identification of two false negatives and one false positive that were due to complexity of underlying genomic change, confirmed by Sanger sequencing. Additionally, the study of the non-EGFR amplicons revealed 33 confirmed unique mutations in 17 genes, with TP53 being the most frequently mutated. Clinical relevance of these finding is discussed.ConclusionsReporting of entire mutational spectrum revealed by targeted sequencing is questionable, at least until the clinically-driven guidelines on reporting of somatic mutations are established. The standardization of sequencing protocols, especially their data analysis components, requires assay-, disease-, and, in many cases, even sample-specific customization that could be performed only in cooperation with clinicians.

[1] Alexander Dobrovic,et al. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase , 2012, Oncotarget.

[2] Karen H. Vousden,et al. Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.

[3] S. Hirohashi,et al. Beta-catenin mutation in carcinoma of the uterine endometrium. , 1998, Cancer research.

[4] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[5] C. Denkert,et al. Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer , 2015, BMC Clinical Pathology.

[6] U. Rapp,et al. Ras oncogenes and their downstream targets. , 2007, Biochimica et biophysica acta.

[7] J. Hainsworth,et al. Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study. , 2016 .

[8] C. Shriver,et al. Management of Incidental Findings in the Era of Next-generation Sequencing , 2015, Current genomics.

[9] S Senan,et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[10] M. Ladanyi,et al. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. , 2015, Cancer discovery.

[11] David M. Thomas,et al. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing , 2014, BMC Medical Genomics.

[12] William Pao,et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[13] R. Edwards,et al. Fast Identification and Removal of Sequence Contamination from Genomic and Metagenomic Datasets , 2011, PloS one.

[14] Edward S. Kim,et al. The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[15] Yi-Song Wang,et al. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[16] M. Loda,et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. , 2010, The American journal of pathology.

[17] S. Kato,et al. Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[19] C. Ishioka,et al. Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays. , 2007, Cancer research.

[20] E. Robertson,et al. Hypoxia Inactivates the VHL Tumor Suppressor through PIASy-Mediated SUMO Modification , 2010, PloS one.

[21] Chloe E Atreya,et al. Expanded RAS: refining the patient population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22] Birgit Funke,et al. College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. , 2015, Archives of pathology & laboratory medicine.

[23] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[24] A. Ferrando,et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. , 2008, Blood.

[25] Masahiko Ando,et al. Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR , 2015, Clinical Cancer Research.

[26] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[27] F. Bertucci,et al. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. , 2006, Journal of the National Cancer Institute.

[28] R. Poppiti,et al. Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[29] Kathleen M Murphy,et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. , 2010, The Journal of molecular diagnostics : JMD.

[30] S. Pilotti,et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma , 2015, Molecular oncology.

[31] J. Li,et al. Correlation of EGFR gene amplification with invasion and metastasis of non-small cell lung cancer. , 2015, Genetics and molecular research : GMR.

[32] M. Murphy,et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[33] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[34] Jeffrey W. Clark,et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35] Jason Li,et al. Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. , 2013, Clinical chemistry.

[36] R. Houlston,et al. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. , 2006, Blood.

[37] E. V. Van Allen,et al. Next-generation sequencing to guide cancer therapy , 2015, Genome Medicine.

[38] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[39] S. Fujita,et al. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations , 2015, BMC Cancer.

[40] E. Robertson,et al. Ubiquitin/SUMO Modification Regulates VHL Protein Stability and Nucleocytoplasmic Localization , 2010, PloS one.

[41] Wei Zhang,et al. Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer , 2011, Clinical Cancer Research.

[42] T. Dörk,et al. ATM missense variant P1054R predisposes to prostate cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43] K. Schmid,et al. The prevalence of the c-kit exon 10 variant, M541L, in aggressive fibromatosis does not differ from the general population , 2011, Journal of Clinical Pathology.

[44] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[45] A. Valsesia,et al. The Growing Importance of CNVs: New Insights for Detection and Clinical Interpretation , 2013, Front. Genet..

[46] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[47] D. Pim,et al. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression , 2004, International journal of cancer.

[48] C. Sander,et al. Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.

[49] Stephen C Peiper,et al. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory. , 2015, Archives of pathology & laboratory medicine.

[50] E. Mardis,et al. Tumor heterogeneity: next-generation sequencing enhances the view from the pathologist’s microscope , 2014, Genome Biology.

[51] J. Blay,et al. Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology , 2014, BMC Cancer.

[52] S. Tanosaki,et al. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia – potential clinical significance , 2002, Leukemia.

[53] Julian Peto,et al. Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synonymous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14 704 first-degree relatives. , 2006, Human molecular genetics.

[54] K. Lillehei,et al. Desmoid-type fibromatoses involving the brachial plexus: treatment options and assessment of c-KIT mutational status. , 2006, Journal of neurosurgery.